

CURRICULUM VITAE

Jay D. Amsterdam, MD

Depression Research Unit
Department of Psychiatry
University of Pennsylvania School of Medicine
Philadelphia, PA 19104

Phone: 856-448-0780

Fx: 856-428-1392

E-mail: jamsterd@mail.med.upenn.edu

University & Medical Education:

University: 1966-1970 BA - American Studies - Syracuse University, Syracuse, New York

Medicine: 1970-1974 MD - Jefferson Medical College, Philadelphia, Pennsylvania

Postgraduate Training & Fellowship Appointments:

1974	Intern in Obstetrics/Gynecology, Upstate Medical Center, Syracuse, New York
1974 - 1977	Resident in Psychiatry, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
1976	Clinical Attachment, Maudsley Hospital at the Institute of Psychiatry, University of London, England
1976 - 1977	Chief Resident in Psychiatry, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
1977 - 1978	Senior Resident, Psychiatric Research Service, Depression Research Unit, Veterans Administration Medical Center, Philadelphia, PA
1978 - 1979	N.I.M.H. Postdoctoral Fellow in Neuropsychopharmacology - Depression Research Unit, Veterans Administration Hospital, and the Department of Psychiatry, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

Academic & Faculty Appointments:

2016 -	Professor of Psychiatry (Emeritus) University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania School of Medicine
1992 - 2016	Professor of Psychiatry University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania School of Medicine
1986 - 1992	Associate Professor of Psychiatry University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
1979 - 1986	Assistant Professor of Psychiatry University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania

Adjunct Academic & Faculty Appointments:

2015 -	Professor of Psychiatry (Adjunct) Cooper Medical School of Rowan University Camden, New Jersey
1988 - 1995	Associate Professor (Adjunct) The Wistar Institute of Anatomy, Philadelphia, Pennsylvania
1983 - 1988	Associate Professor of Psychiatry (Adjunct) Thomas Jefferson University, Philadelphia, Pennsylvania
1978 - 1983	Assistant Professor of Psychiatry (Adjunct) Thomas Jefferson University, Philadelphia, Pennsylvania

Clinical & Hospital Appointments:

1978 - 2014	Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania (Standing Faculty)
1979 - 2016	Director, Depression Research Unit, Hospital of the University of Pennsylvania, Philadelphia, PA
1980 - 1993	Co-Director, Bipolar Disorders & Lithium Clinic
1993 -	Director, Bipolar Disorders & Lithium Clinic
1997 -	Presbyterian Medical Center, Philadelphia, PA

Certification:

1975	Diplomat, National Board of Medical Examiners
1979	Diplomat, American Board of Psychiatry and Neurology

Licensure:

1975 - Pennsylvania MD 016480 E
1989 - New Jersey 54109

Research Experience:

Psychopharmacology of Affective Disorders
Antidepressant Drug Development
Investigational Clinical Trials
Bipolar Affective Disorders
Treatment-resistant Affective Disorders
Molecular Brain Imaging Studies
Psychoneuroendocrinology of Affective Disorders
Psychoimmunovirology of Affective Disorders
Clinical Pharmacokinetics
Integrative and Botnaical Therapy of Anxiety and Mood Disorders

Honors & Awards:

1986 Marie H. Eldredge Award for Research in Affective Disorders, American Psychiatric Association
1988 Curt P. Richter Prize for Research in Psychoneuroendocrinology, International Society of Psychoneuroendocrinology
1989 Fellow of the American Psychiatric Association
1996 Visiting Professor, Karol Marcinkowski Medical Academy of Poznan, Poland
1996 Scholarly Sabbatical, University of Pennsylvania: Serotonin transporter PET imaging
2002 - John Morgan Society
2003 - Distinguished Fellow, American Psychiatric Association
2011 - Distinguished Life Fellow, American Psychiatric Association
2004 - Association of Senior & Emeritus Faculty
2004 - 2005 Philadelphia Top Doc
2005 - 2006 Best Doctors in America
2007 - 2008 Best Doctors in America
2009 - 2010 Best Doctors in America
2011 - 2012 Best Doctors in America
2013 - 2014 Best Doctors in America
2008 - Institute for Translational Medicine & Therapeutics

Membership in Professional & Scientific Societies:

1975 - 1990	American Psychiatric Association (General Member)
1990 - 2003	American Psychiatric Association (Fellow)
2003 - 2010	American Psychiatric Association (Distinguished Fellow)
2010 -	American Psychiatric Association (Distinguished Life Fellow)
1976 - 1981	Royal College of Psychiatrists (Inceptor), London
1975 -	Pennsylvania Psychiatric Society
1978 - 2004	International Society of Psychoneuroendocrinology
1982 - 2005	Society of Biological Psychiatry
1983 - 1995	American Federation for Clinical Research
1985 - 1991	Philadelphia Psychiatric Society (Executive Council)
1987 - 1996	American Association for the History of Medicine
1990 - 1994	American Board of Medical Psychotherapists
1989 - 1992	International Society for the Investigation of Stress
1997 -	David Mahoney Institute of Neurological Sciences
2002 -	John Morgan Scientific Society
2008 -	Institute for Translational Medicine & Therapeutics
2016 -	International Network for the History of Neuropsychopharmacology

Membership on Scientific Journal Editorial Boards:

1986 - 2014	Journal of Affective Disorders - Associate Editor
1987 - 1996	Psychosomatics - Assistant Editor
1995 -	Psychiatric Annals - Editorial Advisory Board
1995 - 2000	Depression - Editorial Advisory Board
2000 - 2005	Journal of Bipolar Disorder - Editorial Advisory Board
2000 - 2009	Progress Neuro-Psychopharmacology & Biological Psychiatry - Editorial Board
2001	Psychiatria Polska - Editorial Advisory Board
2005 -	Current Drug Therapy - Editorial Advisory Board
2015 -	Phytomedicine - Editorial Advisory Board

Membership on Scientific Journal Review Boards:

- Archives of General Psychiatry
- American Journal of Psychiatry
- Biological Psychiatry
- Depression & Anxiety
- Journal of Affective Disorders
- Journal of Clinical Psychiatry
- Journal of Clinical Psychopharmacology
- Journal of Neuropsychiatry and Clinical Neuroscience
- Progress in Neuro-Psychopharmacology & Biological Psychiatry

- Psychoneuroendocrinology
- Psychiatric Annals
- Psychiatry Research
- Psychosomatics
- Psychobiology
- Psychiatry Research Neuroimaging
- Current Drug Therapy
- PhytoMedicine

Membership on Extramural Advisory Committees:

- Program Committee, *IV World Congress of Biological Psychiatry* (1984-5);
- Scientific Advisory Committee, *Second International Conference on Viruses, Immunity, and Mental Health* (1988);
- Program Director, Organizing Committee, *First International Conference on Refractory Depression* (1988);
- Committee on Membership, *Society of Biological Psychiatry* (1988-91);
- NIMH Consensus Panel on Resistant Depression, *National Institutes of Health* (1989);
- Chair, Clinical Research Resource Committee, *Philadelphia Psychiatric Society* (1989-94);
- APA Mood Disorders Review Group for DSM-IV, *American Psychiatric Association* (1989);
- NIMH Workshop Committee on Refractory Depression. *NIMH* (1990);
- NIH Special Emphasis Panel Review Group for Chronic Fatigue Syndrome (CFS) Center Grants, *National Institutes of Health* (August, 1991);
- Organizing Committee, *2nd International Congress on Refractory Depression* (1990-92);
- Program Director, Organizing Committee, *3rd International Conference on Refractory Depression* (1992-95);
- NIH Advisory Panel to the *Project on Informed Consent, Human Research Ethics Group* (1996);
- Expert Consensus Panel, *International Consensus Conferences on Treatment-Resistant Depression* (1996-97);
- Scientific Advisory Panel on Premenstrual Dysphoric Disorder (PMDD), *Society for the Advancement of Women's Health Research* (1998);
- Expert Panel on Neuroendocrine Aspects of Chronic Fatigue Syndrome (CFS), *Chronic Fatigue and Immune Disorder Syndrome Association (in conjunction with the Center for Disease Control (CDC) and the National Institutes of Health (NIH))* (2001)
- Expert Reviewer, *Practice Guideline for the Treatment of Patients With Bipolar Disorder*, Work Group on Bipolar Disorder of the American Psychiatric Association (2001)
- Expert Panel on Immunological Aspects of Chronic Fatigue Syndrome (CFS), *Chronic Fatigue and Immune Disorder Syndrome Association (in conjunction with the Center for Disease Control (CDC) and the National Institutes of Health (NIH))* (2001)
- Consultant, Information Television Network, Project on Depression for Public Television (2003-2004)

- NIMH Special Emphasis Panel Review Group for Translational Research Grants in Mental Disorders, *National Institutes of Mental Health* (October 28, 2005)
- NIMH Special Emphasis Panel Review Group for Educational Research Grants in Mental Health, *National Institutes of Mental Health* (March 13, 2006)
- Advisory Committee, INSIGHT Integrated CME Initiative on Depression, University of Pennsylvania School of Medicine Office of Continuing Medical Education (2006-2007)
- International Society for Bipolar Disorders (ISBD) Task Force report on antidepressant use in bipolar disorders
- International Society for Bipolar Disorders (ISBD) Task Force report on lithium use in bipolar disorder

Past Membership on Pharmaceutical Industry Scientific Panels:

- Eli Lilly and Company
- Somerset Pharmaceuticals, Inc.
- Organon Pharmaceuticals, Inc.
- Lundbeck Pharmaceuticals (Denmark)
- Bristol Myers Squibb, Inc.
- Janssen Pharmaceuticals, Inc.
- SK Bio-Pharmaceutical, Inc.
- Pfizer Pharmaceuticals, Inc.
- Wyeth-Ayerst Pharmaceuticals, Inc.
- UCB Pharma, Inc.
- AstraZeneca, Inc.
- Novartis Pharmaceutical Corp.

Membership on University Committees:

1983 - 1996 Institutional Review Board
 1987 - 1988 Faculty Senate Executive Committee
 1987 - 1988 University Council
 1987 – 1990 Undergraduate Admissions Committee
 1988 - 1989 University Facilities Committee
 1989 - 1991 Student Affairs Committee
 1990 - 1993 University Disability Board
 1996 – 1998 Faculty Grievance Commission
 1996 - 1997 Human Research Ethics Group, Informed Consent
 1997 Regulatory Affairs Review Committee
 1999 Affirmative Action Focus Group
 2003 - 2016 Masters & Doctoral Dissertation Committees - CCEB

Membership on Medical School & Hospital Committees:

1987 - 1989	Student-Faculty Interaction Committee
1986 -	Continuing Medical Education Lecture Series
1988	Ad hoc Committee on Organ Transplantation

1989 - 1993	Pharmacy and Therapeutics Committee
1991 - 1992	Investigational Drug Task Force
1996 - 1998	Admissions Committee
1997	JCAHO Reviewer Committee (Psychiatry)
2001	Credentialing Committee
2002	Research Committee for Strategic Planning
2006	Data Safety Monitoring Board Oversight Committee

Membership on Master & Doctoral Dissertation Committees (since 2005):

- Barbara Posmontier, MSN, CNM, PhD: Doctor of Philosophy in Nursing, School of Nursing, University of Pennsylvania, June, 2006; Title - Functional status and motor activity in postpartum depression. (PhD thesis, 2005-2006).
- Chia-Hao Wang, MS: Master of Science in Biostatistics, CCEB, University of Pennsylvania, May, 2007; Title - Quasi-least squares analysis of rapid cycling in a comparison of venlafaxine versus lithium in the treatment of depression. (MS thesis, 2006-2007).
- Hanjoo Kim, MS: Master of Science in Biostatistics, CCEB, University of Pennsylvania, May, 2008; Title - A closed multiple testing procedure in fixed sequence of families with multiple null hypotheses and its application to the clinical Trial in patients with bipolar II depression. MS thesis, 2006-2007).
- Yimei Li, MS: Master of Science in Biostatistics, CCEB, University of Pennsylvania, May, 2008, Title - Longitudinal analysis for comparison of chamomile versus placebo in anxiety treatment. (MS thesis, 2006-2008).
- Yubing Yao, MS: Master of Science in Biostatistics, CCEB, University of Pennsylvania, May, 2009, Title - Black cohosh and GEE deletion diagnostics (MS thesis, 2008-2009).
- Lola Luo, MS: Master of Science in Biostatistics, CCEB, University of Pennsylvania, April, 2010, Title - Analysis of data for the effect of short-term fluoxetine monotherapy in rapid vs. non-rapid cycling bipolar II patients with major depressive episode. (MS thesis, 2009-2010).
- Bridgette M. Brawner, PhD, APRN: NIH Pathway to Independence Career Development Grant, Post-doctoral Fellowship, School of Nursing, University of Pennsylvania, 2010 – 2016, Title - Integrating biological and behavioral science to improve depression and prevent HIV/STDs among clinically depressed urban adolescent females.

GRANTS & ENDOWMENTS

Research Endowments:

- Jack Warsaw Endowment for Research in Biological Psychiatry (Director) – Private Research Endowment, University of Pennsylvania, Established 1984

Federal & Foundation Research Grants:

1. NIMH Grant: "Hypothalamic-Pituitary-Gonadal Axis in Depression." (Principal Investigator), 1980 - 1981
2. NIMH Grant: "Effect of Lithium on Renal Function." (Co-Investigator), 1980 - 1985
3. NIH Biomedical Research Support Grant: "Inactivation of Herpes Simplex Virus by Lithium Carbonate." (Principal Investigator), 1989 - 1990
4. NIMH Grant: "Borna Disease Virus in Depression Using Nucleic Probes." (Co-Investigator), 1989 - 1994
5. NARSAD Grant: "Arylsulfatase-A Enzyme Variants in Major Depression." (Co-Investigator), 1995 - 1997
6. NARSAD Grant: "Core Body Temperature Alterations in Depression." (Co-Investigator), 1992 - 1995
7. Stanley Medical Research Foundation: "Central Serotonergic-Neuroendocrine Interactions in MDD Using PET Selective 5-HT Ligand." (Principal Investigator), 1995 - 1998
8. Stanley Medical Research Foundation: "Collaborative Study of Borna Virus in Affective Disorders." (Co-Principal Investigator), 1996 - 1998
9. NIMH Grant: "Cognitive Therapy vs. Pharmacotherapy of Major Depression." (Co- Investigator), 1996 - 2001
10. NIMH Grant: "Relapse-prevention of Bipolar II Major Depression." (Principal Investigator), 2001 - 2006
11. Stanley Medical Research Institute: "Acute Antidepressant Therapy in Bipolar II Major Depression." (Principal Investigator), 2002 - 2007

12. NIMH Grant: "Prevention of Depressive Relapse with Cognitive Therapy." (Co-Investigator), 2002 - 2007
13. NIMH Grant: "Major Depression after Minor Injury." (Co-Investigator), 2002 - 2007
14. NIH / NCCAM Grant: "Black Cohosh Therapy for Menopause-related Anxiety" (Principal Investigator), 2005 - 2007
15. NIMH Grant: "SPECT Brain Imaging as a Bio-Marker of Major Depression." (Principal Investigator), 2005 - 2008
16. NIH / NCCAM Grant: "Chamomile Therapy for Generalized Anxiety Disorder." (Principal Investigator), 2005 - 2007
17. NIMH Grant: "Prevention of Depressive Relapse with Cognitive Therapy." Competing Continuation Grant (Co-Investigator), 2007 - 2012
18. NIMH Grant: "Treatment of Bipolar Type II Major Depression." Competing Continuation Grant (Principal Investigator), 2007 - 2012
19. NIMH Grant: "Effect of Psychotherapy on Brain Serotonin Activity" (Principal Investigator), 2007 - 2010
20. NIMH Grant: "Prevention of Relapse & Recurrence of Bipolar Depression" (Principal Investigator), 2009 - 2014
21. NIMH Grant: "Effects of Psychopathology on Prefrontal Cortical Functioning During Goal Directed Behavior" (Co-Investigator), 2009 - 2011
22. NIH / NCCAM Grant: "Long-Term Chamomile Therapy of Generalized Anxiety Disorder" (Principal Investigator), 2009 - 2014
23. NIH / NCCAM Grant: "Rhodiola rosea Therapy of Major Depressive Disorder" (Principal Investigator), 2010 - 2013

Investigator-initiated Research Grants:

1. Double-blind, randomized, fixed dose/plasma level clinical response study; outpatients with endogenous depression. (Principal Investigator) 1980-1981.
2. Double-blind, randomized, fixed dose/plasma level relationship study; determination of 24-hour predictive plasma level test in outpatients with endogenous depression. (Co-Investigator), 1979-1980.
3. Open-label, fixed dose, determination of desipramine and hydroxy-desipramine plasma levels vs. clinical response, outpatients with endogenous depression. (Principal Investigator), 1982-1984.

4. Double-blind, placebo-controlled, high dose perenteral reserpine and tricyclic antidepressant in refractory depression. (Principal Investigator), 1984-1986.
5. Randomized, double-blind, placebo-controlled, cross-over treatment of recurrent herpes genitalis with low dose lithium carbonate. (Principal Investigator), 1987-1988.
6. High-dose, open-label tranylcypromine treatment in patients with chronic, refractory depression. (Principal Investigator), 1987.
7. Randomized, double-blind, placebo-controlled longitudinal study of low dose lithium as a prevention for recurrent herpes genitalis infections. (Principal Investigator), 1988-1991.
8. Randomized, double-blind, placebo-controlled trial of sertraline and desipramine in bipolar patients taking maintenance lithium carbonate. (Principal Investigator), 1989-1991.
9. Determination of core body temperature dysregulation in depression. (Co-Principal Investigator), 1993-95.
10. SPECT brain imaging with HMPAO in patients with major depression. (Principal Investigator), 1994-1995.
11. TRH stimulation test as a predictor of antidepressant response to fluoxetine. (Co-Principal Investigator), 1994-1995.
12. [^{99m}Tc]TRODAT-1 SPECT of brain dopamine transporter availability in major depression. (Co-Investigator), 1999-2002.
13. Double-blind comparison of once vs. twice daily venlafaxine in major depression. (Principal Investigator), 1995-1996.
14. Double-blind, placebo-controlled comparison of sertraline 50 mg vs. 150 mg daily in depressed patients refractory to 50mg daily. (Co-Principal Investigator), 1997-1998.
15. Randomized, double-blind comparison of the efficacy and safety of fluoxetine vs. placebo in relapse-prevention of bipolar type-II major depression. (Principal Investigator), 1998-2001.
16. Randomized, double-blind, placebo-controlled comparison of fluoxetine vs. olanzapine vs. fluoxetine plus olanzapine in bipolar I and II major depression. (Principal Investigator), 1999-2002.
17. Sertraline treatment of dizziness: an open-label study. (Co-Investigator), 2001-2003.
18. Safety and efficacy of s-citalopram in co-morbid major depression and diabetes. (Principal Investigator), 2002-2004.

19. Open label study on the effects of fluoxetine on energy using associated biomarkers in patients with major depression (Principal Investigator), 2003-2004.
20. Safety and efficacy of s-citalopram in the treatment co-morbid major depression and chronic fatigue syndrome (Principal Investigator), 2002-2004.
21. Comparison of the efficacy and safety of Prempro[®] versus Effexor-XR[®] in the treatment of menopause-related anxiety and depression symptoms (Principal Investigator), 2002-2004.
22. I¹²³ADAM selective serotonin re-uptake site imaging agent in patients with major depression and healthy controls. (Co-Investigator), 2004-2005.
23. MAOI efficacy of treatment-resistant depression - A chart review. (Principal Investigator), 2004-2005.
24. Change on 24-hour motor activity as a predictor of duloxetine efficacy in patients with co-morbid major depression and soft tissue discomfort. (Principal Investigator), 2006-2008.
25. Rhodiola rosea therapy of chronic fatigue syndrome. (Principal Investigator), 2009-2011.

Industry-sponsored Research Grants:

1. Bupropion vs. Imipramine vs. Placebo (1977) - Investigator
Double-blind, randomized, outpatients with major depression.
2. Clobazam vs. Diazepam vs. Placebo (1977) - Investigator
Double-blind, randomized, outpatients with anxiety disorder.
3. Triazolam vs. Placebo (1978) - Investigator
Double-blind, randomized, outpatients with mild anxiety.
4. Triazolam vs. Diazepam vs. Placebo (1978) - Investigator
Double-blind, randomized, outpatients with severe anxiety.
5. Alprazolam vs. Placebo (1978) - Investigator
Double-blind, randomized, outpatients with moderate insomnia.
6. Quazepam vs. Placebo (1979) - Investigator
Double-blind, randomized, outpatients with moderate insomnia.
7. Zometapine vs. Desipramine vs. Placebo (1979) – Co-Investigator
Double-blind, randomized, outpatients with primary depression.
8. SAH-52-522 vs. Placebo (1980) – Investigator
Double-blind, randomized, outpatients with chronic anxiety.

9. Desipramine/Chlordiazepoxide vs. Desipramine vs. Chlordiazepoxide vs. Placebo (1981) – Investigator
Double-blind, randomized, outpatients with major depression.
10. Zimelidine vs. Amitriptyline vs. Placebo (1981) – Investigator
Double-blind, randomized, outpatients with depression.
11. Fluoxetine vs. Placebo (1981) – Co-Investigator
Double-blind, randomized, outpatients with major depression.
12. Alprazolam vs. Imipramine vs. Diazepam (1982) – Investigator
Double-blind, placebo-controlled comparison in patients with major depression.
13. Zimelidine vs. Desipramine vs. Placebo (1982) – Principal Investigator
Double-blind, randomized, geriatric (>60 years) outpatients with major depression.
14. ENDO-207 vs. Placebo (1982) – Co-Investigator
Double-blind, randomized, dose-ranging study in depression.
15. Fluoxetine Dosing Study (1982) – Co-Investigator
Double-blind, randomized, open-label study in depressed outpatients, comparing Q.D. vs. B.I.D. dosing.
16. Bupropion "Cross-over" Study (1983) – Principal Investigator
Open-label, randomized, crossover from prior antidepressant to bupropion in "treatment-resistant", endogenously depressed outpatients.
17. Cilobamine vs. Imipramine vs. Placebo (1983) – Principal Investigator
Double-blind, randomized, dose-ranging study, outpatients with major depression.
18. Adinazolam vs. Imipramine (1983) – Principal Investigator
Double-blind, randomized, long-term tolerance study in major (melancholic) depression.
19. Indalpine vs. Imipramine vs. Placebo (1984) – Principal Investigator
Double-blind, randomized comparison in major depression.
20. Buspirone (1984) – Principal Investigator
Open-label trial, high dose for treatment of depression.
21. Adinazolam vs. Imipramine vs. Diazepam vs. Placebo (1985) – Investigator
Double-blind, randomized comparison major depression.
22. Minaprine vs. Placebo (1985) – Principal Investigator
Dose ranging study in patients with major depression and dysthymic disorder.
23. Paroxetine vs. Placebo (1985) – Investigator
Double-blind, randomized comparison in outpatients with major depression.
24. Fluoxetine and Placebo (1986) – Co-Investigator
Double-blind comparison of two dose regimens in refractory depression.

25. Gepirone (1986) – Principal Investigator
Open-label dose ranging in major depression.
26. WY-45,030 (1986) – Investigator
Open-label dose ranging in major depression.
27. Gepirone (1987) – Principal Investigator
Open-label dose ranging in major depression with a randomized, double-blind, cross-over to placebo in treatment responders.
28. Buspirone (1987) – Principal Investigator
Double-blind, placebo-controlled study in patients with major depression.
29. Sertraline (1987) – Principal Investigator
Double-blind, placebo-controlled comparison of sertraline vs. amitriptyline in major depression.
30. Wy-45,030 (1987) – Co-Investigator
Double-blind, placebo-controlled study of three doses of venlafaxine in major depression.
31. CP-76,593 (1988) – Principal Investigator
Multicenter, double-blind, placebo-controlled trial of CP-76,593 in outpatients with major depressive disorder.
32. Nefazodone (1989) – Investigator
Double-blind, placebo-controlled trial of nefazodone and imipramine in patients with major depression.
33. Sertraline (1989) – Co-Investigator
Relationship between thyroid axis function and clinical course in depressed patients treated with sertraline.
34. Sertraline (1989) – Co-Investigator
Double-blind, placebo-controlled comparison of sertraline and fluoxetine in outpatients with major depression.
35. Sertraline (1989) – Co-Investigator
Double-blind, placebo-controlled study of sertraline effect on polysomnographic recordings in major depression.
36. Gepirone (1989) – Principal Investigator
A double-blind, placebo-controlled comparison of gepirone and imipramine in the treatment of geriatric outpatients with major depression.
37. Sibutramine (1989) – Principal Investigator
A double-blind, placebo-controlled study comparing the efficacy, safety, and tolerability of sibutramine and desipramine in outpatients with major depression.
38. Fluoxetine (1990) – Principal Investigator

Fluoxetine vs. placebo: longitudinal assessment of treatment outcome in patients with major depression.

39. Ceranopril (SQ 29,582) (1990) – Principal Investigator

Open-label pilot study in patients with recurrent major depressive disorder.

40. Paroxetine (1991) – Co-Investigator

Double-blind, placebo-controlled comparison of paroxetine and fluoxetine in major depression.

41. Sertraline (1991) – Principal Investigator

Open trial of sertraline in patients with major depression intolerant to fluoxetine.

42. Fluoxetine / Alprazolam (1991) – Principal Investigator

Treatment of fluoxetine induced "jitteriness syndrome" with alprazolam in patients with major depression.

43. Buspirone (1992) – Principal Investigator

Double-blind placebo-controlled, multi-center trial of the safety and efficacy of buspirone in anxious patients with coexisting depression.

44. Amesergide (1992-1993) – Principal Investigator

Double-blind placebo controlled comparison of amesergide and fluoxetine in MDD patients with normal and short REM latency.

45. Venlafaxine (1992-1994) – Principal Investigator

Six-month, open-label evaluation of venlafaxine, followed by randomized, double-blind, placebo-controlled one year prophylactic treatment.

46. Flesinoxan (1995) – Principal Investigator

Flesinoxan in the treatment of generalized anxiety disorder: A multi-center, double-blind, parallel, placebo-controlled, dose range study in outpatients.

47. Paroxetine (1995) – Principal Investigator

Efficacy and tolerability of Paxil vs. imipramine vs. placebo in bipolar patients taking lithium carbonate with major depression.

48. Fluoxetine, sertraline, paroxetine (1996-1997) – Principal Investigator

Fluoxetine vs. sertraline and paroxetine in major depression: comparison of discontinuation-emergent signs and symptoms.

49. Selegiline (1997) – Principal Investigator

Double-blind, placebo-controlled assessment of the efficacy and safety of selegiline transdermal system in major depression.

50. Olanzapine vs. placebo (1997-1999) – Principal Investigator

Double-blind, placebo-controlled comparison of the efficacy and safety of olanzapine in manic or hypomanic outpatients taking a concurrent mood stabilizer.

51. Fluoxetine, sertraline, paroxetine (1997-1998) – Principal Investigator

Physiological and endocrinological correlates of treatment interruption of fluoxetine, sertraline or paroxetine in remitted patients on maintenance therapy.

52. Fluoxetine (1997-1998) – Principal Investigator

Double-blind, placebo-controlled comparison of the efficacy and safety of enteric-coated fluoxetine vs. daily fluoxetine vs. placebo in relapse-prevention.

53. MK-0869 Substance P Inhibitor (1998) – Principal Investigator

Double-blind, placebo-controlled, dose-ranging study of the safety and efficacy of MK-0869 in patients with major depression.

54. YKP10A (1999) – Principal Investigator

Randomized, double-blind, dose-ranging study of YKP10A in patients with major depression.

55. L-759,274 Substance P Inhibitor (1998-1999) – Principal Investigator

Double-blind, placebo-controlled, dose-ranging study of L-759,274 in patients with major depression.

56. Selegiline (1998-1999) – Principal Investigator

Double-blind, placebo-controlled assessment of the efficacy and safety of selegiline transdermal system in major depression.

57. Olanzapine / Valproic Acid (1999-2000) – Principal Investigator

Double-blind, randomized comparison of olanzapine vs. valproic acid in manic inpatients, followed by 1-year, double-blind maintenance therapy.

58. Mirtazapine (1999) – Principal Investigator

Double-blind, randomized comparison of mirtazapine vs. sertraline in depressed patients with prior SSRI treatment failure.

59. Olanzapine (1999-2000) – Principal Investigator

Double-blind, comparison of olanzapine vs placebo in 1-year relapse-prevention of recovered bipolar I patients.

60. s-Citalopram (1999-2000) – Principal Investigator

Double-blind, placebo-controlled comparison of the efficacy and safety of citalopram vs. s-citalopram in major depression.

61. s-Citalopram (1999-2000) – Principal Investigator

Double-blind, placebo-controlled comparison of the efficacy and safety of citalopram vs. s-citalopram in panic disorder.

62. Reboxetine (1999-2000) – Principal Investigator

Double-blind, placebo-controlled, assessment of the efficacy and safety in patients with treatment-resistant major depression.

63. Selegiline (1999-2000) – Principal Investigator

Double-blind, placebo-controlled, 9-month assessment of the efficacy and safety of selegiline transdermal system in relapse-prevention of major depression.

64. Olanzapine vs. placebo (2000-2001) – Principal Investigator
Double-blind, placebo-controlled study of olanzapine in relapse-prevention of bipolar disorder.
65. Gepirone (2000-2002) – Principal Investigator
Double-blind, placebo-controlled study of gepirone versus fluoxetine in outpatients with atypical major depression.
66. s-Citalopram (2000-2001) – Principal Investigator
Double-blind, placebo-controlled comparison of the efficacy and safety of citalopram vs. s-citalopram in generalized anxiety disorder.
67. Ziprasidone (2001-2002) - Principal Investigator
Addition of ziprasidone to sertraline in treatment-resistant depression without psychotic features.
68. Gepirone (2002-2003) – Principal Investigator
Double-blind, placebo-controlled study of gepirone versus paroxetine in outpatients with atypical major depression.
69. Atomoxetine vs. placebo (2003-2004) – Principal Investigator
Noradrenergic monotherapy and noradrenergic augmentation of SSRI therapy in patients with depression incompletely responsive to SSRI monotherapy.
70. Olanzapine vs. Divalproex (2005-2006) – Principal Investigator
Olanzapine versus divalproex and placebo in the treatment of mild to moderate mania associated with bipolar I disorder (Protocol F1D-MC-HGKQ)
71. Saredutant vs. placebo (2006-2007) – Principal Investigator
Randomized, 24-52 week, double blind, placebo-controlled study of the efficacy, safety, and tolerability of saredutant in the prevention of relapse of depressive symptoms in outpatients with major depressive disorder who achieved an initial response to treatment with saredutant
72. Agomelatine vs. paroxetine vs. placebo (2007-2009) - Principal Investigator
Randomized, 8-week, double blind, placebo-controlled study of the efficacy, safety, and tolerability of agomelatine in the treatment of major depressive disorder, with a 52-week, open label treatment with agomelatine.
73. r-Modafinil vs. placebo (2007-2008) - Principal Investigator
An 8-week, double-blind, placebo-controlled, parallel group, fixed dosage study of the efficacy and safety of r-modafinil treatment as adjunctive therapy in bipolar type I major depression.

Jay D. Amsterdam
September 29,2016